Natco Pharma Limited has informed the Exchange about Superannuation of Dr. Muddasaani Pulla Reddy, Executive Vice President - R & D and Mr. CH Srinivas, Senior Vice President Demand & Supply and also Resignation of Mr. R. Sridhar Reddy Senior Vice President GCQA with effect from the closure of business hours on 30th June, 2025
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Smallcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma has informed the stock exchanges that two senior executives — Dr. Muddasaani Pulla Reddy, Executive Vice President – R&D, and Mr. CH Srinivas, Senior Vice President – Demand & Supply — are retiring (superannuating) from the company with effect from the close of business on 30th June 2025. Additionally, Mr. R. Sridhar Reddy, Senior Vice President – Global Corporate Quality Assurance (GCQA), has resigned from the company, also effective 30th June 2025, as per his resignation letter dated 30th April 2025. None of these executives held board or CEO/CFO positions. The CEO, Mr. Rajeev Nannapaneni, remains in charge.
This is a routine senior-level transition with three senior management exits on the same day, but none at the board or CEO level. Shareholders should watch for any company communication on replacements, especially in the R&D and quality functions, which are critical to a pharma business. Short-term stock impact is likely minimal.